국가: 오스트레일리아
언어: 영어
출처: Department of Health (Therapeutic Goods Administration)
prasterone, Quantity: 6.5 mg
Theramex Australia Pty Ltd
Pessary
Excipient Ingredients: Hard fat
Vaginal
28 pessaries, 7 pessaries (starter pack)
(S4) Prescription Only Medicine
INTRAROSA is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.
Visual Identification: Intrarosa is a white to off-white, bullet-shaped pessary, approximately 28 mm long and 9 mm in diameter at its widest end. The product is supplied with six applicators.; Container Type: Blister Pack; Container Material: PVC/PE; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius
Registered
2023-06-16
INTRAROSA ® prasterone 6.5 mg pessary Theramex Australia Pty Ltd Version 2 – SEP 2023 Page 1 of 16 This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems. AUSTRALIAN PRODUCT INFORMATION INTRAROSA ® PRASTERONE 6.5 MG PESSARY 1 NAME OF THE MEDICINE Prasterone 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each pessary contains 6.5 mg of prasterone in hard fat. For the full list of excipients, see section 6.1 List of excipients. 3 PHARMACEUTICAL FORM INTRAROSA is a white to off-white, bullet-shaped pessary, approximately 28 mm long and 9 mm in diameter at its widest end. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS INTRAROSA is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms. 4.2 DOSE AND METHOD OF ADMINISTRATION DOSAGE INTRAROSA is administered intravaginally with the use of the provided applicator or with fingers. One pessary is administered once a day at bedtime. For the treatment of postmenopausal symptoms, INTRAROSA should only be initiated for symptoms that adversely affect quality of life. In all cases, a careful appraisal of the risks and benefits should be reassessed at least every 6 months (or as clinically appropriate) and INTRAROSA should only be continued as long as the benefit outweighs the risk. If a dose is forgotten, it should be taken as soon as the woman remembers. However, if the next dose is due in less than 8 hours, the woman should skip the missed pessary. Do not use two pessaries to make up for a forgotten dose. METHOD OF ADMINISTRATION If INTRAROSA is placed in the vagina using the provided applicator: 1. Activate the applicator (by pulling back the plunger) before use. 2. Place the flat end of the pessary into the open end of the activated applicator. INTRAROSA ® prasterone 6.5 mg pessary Theramex Australia Pty Ltd Version 2 전체 문서 읽기